Format

Send to

Choose Destination
J Clin Gastroenterol. 2015 Nov-Dec;49 Suppl 1:S46-9. doi: 10.1097/MCG.0000000000000351.

Role of Probiotics in Crohn's Disease and in Pouchitis.

Author information

1
Clinical Hepato-Gastroenterology Unit, Division of Gastroenterology & Digestive Endoscopy, S.Raffaele University Hospital, Milan, Italy.

Abstract

The alterations in the gut microbiota observed in patients with inflammatory bowel disease and in particular in Crohn's disease and in ulcerative colitis patients with pouchitis, provide the rationale for administering probiotic agents in the medical treatment of those conditions. In the maintenance treatment of inactive Crohn's disease probiotics, when administered alone, were found ineffective in preventing clinical and/or endoscopic recurrence. By contrast, a combination of a probiotic agent (eg, Saccharomyces boulardii) with standard pharmacological therapy can promote clinical benefit. In patients with pouchitis, so far only the probiotic mixture VSL #3 proved to effectively prevent relapses after successful antibiotic treatment of active inflammation. Further controlled studies, enrolling higher numbers of patients, are needed to better identify the exact role of probiotics in this area.

PMID:
26447964
DOI:
10.1097/MCG.0000000000000351
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center